November 23, 2021Open Access
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
Key Points
Key points are not available for this paper at this time.
Abstract
Nct03671148.